The BRAFi‐resistant tumor, WM3936‐1, was derived from a BRAFV600E mutant patient who developed a subcutaneous lesion harboring de novo NRAS (Q61K) and PI3KCA (H1047Y) mutations after 9 months of treatment with the BRAFi dabrafenib (Krepler et al, 2016). The gene discussed is NRAS; the disease is neoplasm.